@article{b6b681a67e2845279f33bd56ba665a72,
title = "Hypoglycemia and Glycemic Control in Older Adults With Type 1 Diabetes: Baseline Results From the WISDM Study",
abstract = "Background: Knowledge regarding the burden and predictors of hypoglycemia among older adults with type 1 diabetes (T1D) is limited. Methods: We analyzed baseline data from the Wireless Innovations for Seniors with Diabetes Mellitus (WISDM) study, which enrolled participants at 22 sites in the United States. Eligibility included clinical diagnosis of T1D, age ≥60 years, no real-time continuous glucose monitoring (CGM) use in prior three months, and HbA1c <10.0%. Blinded CGM data from 203 participants with at least 240 hours were included in the analyses. Results: Median age of the cohort was 68 years (52% female, 93% non-Hispanic white, and 53% used insulin pumps). Mean HbA1c was 7.5%. Median time spent in the glucose range <70 mg/dL was 5.0% (72 min/day) and <54 mg/dL was 1.6% (24 min/day). Among all factors analyzed, only reduced hypoglycemia awareness was associated with greater time spent <54 mg/dL (median time of 2.7% vs 1.3% [39 vs 19 minutes per day] for reduced awareness vs aware/uncertain, respectively, P =.03). Participants spent a mean 56% of total time in target glucose range of 70-180 mg/dL and 37% of time above 180 mg/dL. Conclusions: Over half of older T1D participants spent at least an hour a day with glucose levels <70 mg/dL. Those with reduced hypoglycemia awareness spent over twice as much time than those without in a serious hypoglycemia range (glucose levels <54 mg/dL). Interventions to reduce exposure to clinically significant hypoglycemia and increase time in range are urgently needed in this age group.",
keywords = "continuous glucose monitoring, hyperglycemia, hypoglycemia, type 1 diabetes",
author = "{for the WISDM Study Group} and Carlson, {Anders L.} and Kanapka, {Lauren G.} and Miller, {Kellee M.} and Ahmann, {Andrew J.} and Chaytor, {Naomi S.} and Steven Fox and Lisa Kiblinger and Davida Kruger and Levy, {Carol J.} and Peters, {Anne L.} and Rickels, {Michael R.} and Maamoun Salam and Shah, {Viral N.} and Young, {Laura A.} and Kudva, {Yogish C.} and Richard Pratley",
note = "Funding Information: The author(s) declared the following potential conflicts of interest with respect to the research, authorship, and/or publication of this article: ALC reports grants from T1DExchange, during the conduct of the study; grants and personal fees from Sanofi, grants and personal fees from NovoNordisk, grants and personal fees from Medtronic, grants and personal fees from Dexcom, grants and personal fees from Eli Lilly, personal fees from Insulet, grants from Abbott, outside the submitted work. In addition, ALC has a patent Treatment of hypoglycemia unawareness with intranasal insulin pending to HealthPartners Institute. LGK has no disclosures. KMM has no disclosures. AJA reports grants from Helmsley Charitable Trust and JDRF, during the conduct of the study; grants and personal fees from Dexcom, grants from Medtronic, grants and personal fees from Lilly, personal fees from Novo Nordisk, personal fees from MannKind, personal fees from Sanofi, outside the submitted work. NSC reports grants from Jaeb Center for Health Research, during the conduct of the study; personal fees from Eli Lilly, outside the submitted work. SF has no disclosures. LK does not currently act as a speaker for DexCom and has not worked with the company since March 2018. DK has no disclosures. CJL has no disclosures. ALP has no disclosures. MRR has no disclosures. MS reports other from JDRF, other from Helmsley Charitable Trust, other from DEXCOM, during the conduct of the study; other from Mylan, outside the submitted work. VNS reports grants from National Institute of Health, grants from Sanofi US, grants from Mylan/GmbH, grants from NovoNordisk, grants from VTV therapeutics, outside the submitted work. LAY has no disclosures. YCK reports grants from JDRF, other from Dexcom, during the conduct of the study; other from Dexcom, other from Medtronic, other from Tandem Diabetes, outside the submitted work; in addition, YCK has a patent Estimation of insulin sensitivity from CGM and subcutaneous insulin delivery in T1D issued. RP has no disclosures. Dr Kellee Miller is the guarantor of this work, as such, and had full access to all the data in the study and takes responsibility for the integrity of the data and accuracy of the data analysis. Material support was provided by Dexcom. Funding Information: The author(s) disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: This study was supported by the Juvenile Diabetes Research Foundation (grant 3-SRA-2017-425-M-R) and the Leona M. and Harry B. Helmsley Charitable Trust. Publisher Copyright: {\textcopyright} 2019 Diabetes Technology Society.",
year = "2019",
doi = "10.1177/1932296819894974",
language = "English",
volume = "15",
pages = "582--592",
journal = "Journal of Diabetes Science and Technology",
issn = "1932-2968",
number = "3",
}